Health2Sync and Novo Nordisk Pharma Korea, Ltd. Launch Smart Cap Mallya® for FlexTouch® Insulin Pens Integration in South Korea, Enhancing insulin administration via Digital Diabetes Care
This innovation comes at a critical moment. Managing insulin administration records is a challenging task for both diabetes patients and healthcare professionals. In fact, a multinational survey of diabetes patients receiving insulin treatment and physicians treating diabetes patients found that 27.6% of patients experience difficulty administering insulin at the prescribed time or with meals. In the same study, 54.5% of physicians reported that their patients experience difficulty administering insulin at the prescribed time or with meals.
Mallya®, when paired with Health2Sync's connected ecosystem, significantly lowers this burden. Patients using FlexTouch® insulin pens can now have their dosage, time, and frequency data recorded and visualized in real time within the SugarGenie app.
'This integration is connecting yet another integral part in digital diabetes care,' said Ed Deng, CEO and Co-founder of Health2Sync. 'By connecting the data of Mallya® to SugarGenie, we're improving accuracy in insulin tracking and expanding the depth of data available to patients and care teams. Our platform enables insulin logs to be viewed alongside blood glucose, meals, and physical activity, offering a full circle understanding of each patient's health context.'
Deng continued: 'For healthcare professionals, this means faster, smarter decisions. Our care provider portal lets clinicians view real-time patient data We're turning disconnected data points into a unified, actionable picture of care, without placing additional burden on patients.'
SugarGenie's integration with Mallya® supports remote care models and automated record-keeping—an increasingly critical combination for long-term chronic condition management in South Korea. With its clean interface, real-time sync, and care team dashboard, SugarGenie is a key digital infrastructure in Korea's diabetes treatment landscape.
'Digital healthcare has become a key tool in enhancing the efficiency and convenience of diabetes treatment,' said Kasper Roseeuw Poulsen, General Manager of Novo Nordisk Pharma Korea, Ltd.. 'For over a century, Novo Nordisk has supported patients through holistic solutions, and our collaboration with Health2Sync is also a continuation of that commitment. We hope this strategic collaboration will help create a more systematic and efficient treatment environment for both patients and healthcare professionals in Korea.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
11 hours ago
- Malaysian Reserve
CIBC Recognized as a Leading Workplace for Disability Inclusion
TORONTO, July 25, 2025 /CNW/ – CIBC announced today it has been recognized as a Best Place to Work for Disability Inclusion after earning a top score on the 2025 Canada Disability Index®. This recognition underscores CIBC's ongoing commitment to matching talent to opportunity and promoting a workplace where all team members can flourish. The Disability Index® is a leading third-party benchmarking tool for workplace disability inclusion, and measures performance across key areas such as culture and leadership, enterprise-wide access, employment practices, community engagement, and supplier inclusion. 'At CIBC, inclusion is the cornerstone of our bank's culture. Building a workforce that reflects the clients and communities we serve allows for unique perspectives, experiences, and drives innovation,' said Sandy Sharman, Group Head, People, Culture and Brand, CIBC. 'This recognition reinforces our commitment to supporting our team members and empowering them to achieve their ambitions.' By achieving this distinction, CIBC joins hundreds of global organizations dedicated to advancing accessibility and supporting 1.3 billion people with disabilities worldwide1. To learn more about our commitments, visit Accessibility at CIBC. About CIBC CIBC is a leading North American financial institution with 14 million personal banking, business, public sector and institutional clients. Across Personal and Business Banking, Commercial Banking and Wealth Management, and Capital Markets, CIBC offers a full range of advice, solutions and services through its leading digital banking network, and locations across Canada, in the United States and around the world. Ongoing news releases and more information about CIBC can be found at _____________________1 World Health Organization. 'Disability and Health.' WHO, 13 March 2023.
Malaysian Reserve
2 days ago
- Malaysian Reserve
OSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring Technology
BELLEVUE, Wash. and SEOUL, South Korea, July 24, 2025 /PRNewswire/ — OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical and wellness innovation, today announced it has signed a term sheet ('Term Sheet') with Woori IO Co., Ltd. ('WORIO'), a South Korean medical device company developing next-generation noninvasive glucose monitoring technology. The agreement sets forth certain key terms for a strategic acquisition of WORIO by OSR Holdings' Korean affiliate, OSR Holdings Co., Ltd. ('OSRK'). Under the proposed structure, WORIO will become a wholly owned subsidiary of OSRK. Shareholders of WORIO will receive newly issued shares of OSRK through the share exchange and may be eligible to convert them into OSRH common stock traded on NASDAQ, subject to certain conditions including '$10 per OSRH share' WORIO shareholders may convert their OSRK shares into OSRH shares at a fixed exchange ratio of 1 OSRK share = 12.96 OSRH shares, provided that OSRH's stock price reaches $10.00 at least once within three years following the signing of the Term Sheet. If this condition is not met, the parties have agreed to renegotiate in good faith. The agreement includes a 6-month exclusivity period, during which OSRK will conduct confirmatory legal and financial due diligence with a target to complete this transaction within this exclusivity proprietary platform uses near-infrared spectroscopy (NIRS) to measure glucose without needles, sensors, or skin penetration — representing a truly noninvasive alternative to today's continuous glucose monitors (CGMs). Its solution aims to eliminate the burden of pain and daily finger pricks for millions of people with diabetes. According to recent global market research, the blood glucose monitoring devices market is expected to exceed $40 billion by 2030, growing at a CAGR of 8–10%, driven by rising diabetes prevalence and the convergence of medical technology with consumer electronics. Demand for noninvasive and wearable monitoring systems is expected to be a major growth driver. Dexcom, one of the market leaders in minimally invasive CGM which is the current standard of care has more than $32 billion in market capitalization (as of July 11), underscoring the significant commercial potential of advanced glucose monitoring solutions. Noninvasive alternatives hold tremendous promise and are poised to become an integral part of diabetes management in the future. WORIO has completed a proof-of-concept study with the Korea University Hospital (Guro) to validate the accuracy and effectiveness of its prototype devices and the data measured by them, based on which the company plans to enter a larger confirmatory trial to be registered with the Ministry of Food and Drug Safety (MFDS) of Korea for medical device approval pathway. WORIO's noninvasive technology is well positioned to be integrated into wearable glucose monitoring devices such as smart watches — WORIO has been selected by Samsung Electronics' innovative startup program ('C-Lab Outside') in Q1 2025.'We believe this initial milestone with Woori IO aligns strongly with our mission to accelerate breakthrough healthcare innovations with global impact,' said Peter Hwang, CEO of OSRH. 'Woori IO's breakthrough noninvasive glucose monitoring platform, coupled with its high-profile partnership with global companies, puts OSRH in a position to become a first mover in this fast-growing global market.'Following the signing of this Term Sheet, both parties will proceed with due diligence and aim to execute definitive agreements within the 6 months exclusivity period. About OSR Holdings, Inc. OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness to support global health outcomes. Through its subsidiaries, OSRH is engaged in immuno-oncology, regenerative biologics, and medical device distribution. OSRH's vision is to acquire and operate a portfolio of innovative healthcare and wellness companies, improving patient care through cutting-edge research and development. For more information, visit About Woori IO Co., Ltd. Woori IO is a medical device company based in Jeonju, South Korea, focused on the development of noninvasive biosensing solutions. Its proprietary NIRS-based glucose monitoring system enables accurate, pain-free, and user-friendly diabetes management, with strong potential for wearable integration. For more information, visit Contact:Investor RelationsOSR Holdings, IR@ Website:
Malaysian Reserve
2 days ago
- Malaysian Reserve
British Columbia Joins Other Provincial Public Drug Plans Now Reimbursing FOQUEST® on their Formulary for Attention Deficit Hyperactivity Disorder (ADHD)
TORONTO, July 23, 2025 /CNW/ – Elvium Life Sciences is pleased to announce the addition of FOQUEST® (methylphenidate hydrochloride controlled release capsules) to the British Columbia1 PharmaCare formulary and First Nations Health Authority (FNHA) Pharmacy Benefit. With provincial funding in place in British Columbia, FOQUEST® is now reimbursed from coast to coast on all provincial drug plans across Canada. 'Public funding in British Columbia ensures equitable access to ADHD treatments in BC,' said Juanita Beaudry, Executive Director of the Centre for ADHD Awareness (CADDAC) 'This latest approval now provides access across Canada to another treatment option for patients.' British Columbia now joins Alberta2, Saskatchewan3, Manitoba4, Ontario5, Quebec6, Atlantic Canada7,8,9,10, the Non-Insured Health Benefit Plan11 and Correctional Service Canada in providing public formulary coverage for FOQUEST® for the treatment of ADHD in patients aged six years and older. 'Elvium Life Sciences is very pleased that British Columbia has now included Foquest on the BC PharmaCare Formulary to give physicians an additional choice for their ADHD patients who require public coverage,' said Jodan Ratz, Country Medical Director at Elvium Life Sciences. 'We thank the province for its decision which now means that all ADHD patients aged six years of age and older have equivalent access to Foquest should this be the right treatment for them.' See the full Canadian Product Monograph for FOQUEST®12 The Product Monograph for FOQUEST® contains a Serious Warning and Precaution for drug dependence, emphasizing that abuse of FOQUEST® can lead to dependence. Healthcare professionals should assess the risk of abuse prior to prescribing FOQUEST®, including in patients with a history of drug dependence or alcoholism, and monitor for signs of abuse and dependence while patients are on therapy. FOQUEST® is a once-daily, long-acting methylphenidate controlled-release capsule for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients greater than or equal to six years of age. The maximum daily dose of FOQUEST® for children and adolescents (6 to <18 years old) is 70mg, and the maximum daily dose for adults (≥18 years old) is 100 mg. Adverse events observed with FOQUEST® treatment mainly reflect side effects commonly associated with methylphenidate use. Very common adverse events reported by patients treated with FOQUEST® were headache, insomnia, decreased appetite and abdominal pain. Most of the events were mild to moderate in severity. About Elvium Life Sciences Elvium Life Sciences is an independent associated company of Purdue Pharma (Canada), that focuses on specialty pharmaceutical products committed to providing treatment options for patients who suffer from the symptoms of Attention Deficit/Hyperactivity Disorder (ADHD) and products for ophthalmology. For more information, please visit FOQUEST® is a registered trademark of Purdue Pharma and is used under licence. References: 1. Available at: Accessed July 23, 2025 2. Available at: Accessed July 18, 2025 3. Available at: Accessed July 18, 2025 4. Available at: Accessed July 18, 2025 5. Available at: Accessed July 18, 2025 6. Available at: Accessed July 18, 2025 7. Available at: Accessed July 18, 2025 8. Available at: Accessed July 18, 2025 9. Available at: Accessed July 18, 2025 10. Available at: Accessed July 18, 2025 11. Available at: Accessed July 18, 2025. 12. Available at:
